Feb. 24, 2016, Toronto — In announcing the renewal of the licence for its main production facility in the Toronto area, Bedrocan Canada Inc. is re-asserting its advocacy efforts to remove sales tax from medical cannabis.
A petition has been submitted to the House of Commons.
This is a promising step forward for a letter-writing campaign that started less than a month ago respectfully asking the Hon. Bill Morneau, minister of finance, to “zero-rate” medical cannabis, thereby removing sales tax on it.
Once achieved, this change will remedy an unjust financial burden on patients, and bring a viable treatment option in line with the treatment of other prescription medicines.
Bedrocan Canada, a subsidiary of Canopy Growth Corporation, is dedicated to advancing every aspect of medical cannabis, from clinical research to physician education. As Canada’s cannabis laws evolve, Bedrocan Canada will remain committed to improving the body or knowledge, affordability and accessibility of medical cannabis.
“We are committed to advocating for patient issues, and ensuring that the patient’s voice does not get lost as a framework for non-medical cannabis is established,” said Bruce Linton, chairman and CEO of Canopy Growth.
“Our commitment to affordability dates back to May 2014 when we filed a request for review of this rule by the Canada Revenue Agency. This latest petition reflects our ongoing commitment to advance the issue of affordability however we can.”
Those supporting the sales tax issue can visit https://petitions.parl.gc.ca/en/Petition/Sign/e-190 to sign the petition and join as a partner in driving this important message forward.
Print this page